沙利度胺、低剂量地西他滨联合治疗骨髓增生异常综合征的临床效果评价
Clinical Effect Evaluation of Combination Therapy of Thalidomide and Low-Dose Decitabine in Treatment of Myelodysplastic Syndrome
宋丽丽 1郜晓 1许纯 1朱凯1
作者信息
- 1. 张家港市中医医院 肿瘤血液病科,江苏 张家港 215600
- 折叠
摘要
目的 分析沙利度胺、低剂量地西他滨联合治疗骨髓增生异常综合征的临床效果.方法 选取2018年1月—2022年12月在本院就诊的90例骨髓增生异常综合征患者作为研究对象,并依据不同治疗方法将其分为观察组和对照组,每组45例.其中,对照组接受沙利度胺治疗,观察组应用沙利度胺、低剂量地西他滨结合治疗,治疗后比较治疗总有效率和血象指标.结果 观察组的治疗效果在完全缓解(CR)和总体缓解率(ORR)方面明显优于对照组,差异有统计学意义(P<0.05).观察组的治疗后血象相关指标显著高于对照组值,差异有统计学意义(P<0.05).结论 沙利度胺和低剂量地西他滨的联合治疗在改善MDS患者的生存率和疾病控制率方面显示出潜力.
Abstract
Objective To analyze clinical effect of thalidomide combined with low-dose dexamethasone in treatment of myelodysplastic syndrome.Methods The paper chose 90 patients with myelodysplastic syndrome in the hospital from January 2018 to December 2022 as study subjects,evaluated and compared total effective rate of treatment and blood count indicators comprehensively.Results Treatment effect in observation group was significantly better than control group in terms of complete response(CR)and overall response rate(ORR),with statistical significance(P<0.05).Post-treatment value in observation group was significantly higher than control group,difference was statistically significant,indicating treatment in observation group was significant better,(P<0.05).Conclusion Combination of thalidomide and low-dose dexamethasone has potential in improving survival and disease control rates of MDS patients.
关键词
骨髓增生异常综合征/地西他滨/病态造血Key words
Myelodysplastic syndrome/Decitabine/Pathological hematopoiesis引用本文复制引用
出版年
2024
NETL
NSTL
万方数据